In a patient with a history of prostate cancer treatment who now has moderate erectile dysfunction, neurogenic and overactive bladder symptoms, and an International Prostate Symptom Score that increased from 3 to 7, is it more likely than not that these findings are sequelae of the prostate cancer therapy, and what first‑line management should be recommended?

Causality Assessment and Management of Post-Prostate Cancer Treatment Sequelae

Yes, the erectile dysfunction, neurogenic bladder, and overactive bladder symptoms are more likely than not directly caused by the prostate cancer treatment, and first-line management should be PDE-5 inhibitors (sildenafil, vardenafil, or tadalafil) for erectile dysfunction, with consideration of combination therapy using tadalafil plus mirabegron for the mixed urinary symptoms.

Establishing Causality

The claim that these conditions are "at least as likely as not" related to prostate cancer treatment is strongly supported by established evidence. All prostate cancer treatments—whether radical prostatectomy, radiation therapy, or androgen deprivation therapy—are recognized causes of both erectile dysfunction and lower urinary tract symptoms 1.

Erectile Dysfunction Causality

The pathophysiology you've outlined is accurate and well-established:

• After radical prostatectomy: ED occurs immediately due to cavernosal nerve injury during surgical dissection, with rates of 60-89% depending on nerve-sparing technique 1
• After radiation therapy: ED develops gradually over 6-36 months due to progressive vascular injury and endothelial damage, affecting up to 84% of patients 1
• With ADT: Hormonal suppression directly impairs libido and erectile tissue function, with ED rates reaching 85% 1

The moderate severity documented in treatment notes and the temporal relationship to prostate cancer therapy clearly establish causation.

Bladder Dysfunction Causality

The neurogenic and overactive bladder symptoms with IPSS progression from 3 to 7 are consistent with radiation-induced bladder changes. Radiotherapy causes impaired bladder compliance, decreased capacity, and de novo detrusor overactivity, particularly with longer follow-up 2. The literature you cited correctly notes that resolution of bladder outlet obstruction is less likely after radiation compared to surgery, and new-onset overactive bladder commonly develops post-radiation.

First-Line Management Algorithm

For Erectile Dysfunction

Start with PDE-5 inhibitors as first-line therapy 1, 3:

1. Initial trial: Begin with sildenafil, vardenafil, or tadalafil at conservative doses, titrating to maximum as needed
2. Timing considerations:
   • For post-surgical patients: Recovery can continue up to 2-4 years, so revisit PDE-5 inhibitors even if initially unsuccessful 1
   • For post-radiation patients: The delayed onset (6-36 months) means treatment timing should align with symptom progression 1
3. Early rehabilitation: Although controversial, early PDE-5 inhibitor use may preserve smooth muscle and improve outcomes through increased tissue oxygenation 1

Critical contraindication: Verify the patient is not taking oral nitrates, as this combination causes dangerous hypotension 3

For Mixed Urinary Symptoms

Given the combination of neurogenic bladder, overactive bladder, and IPSS of 7, consider tadalafil 5mg plus mirabegron 50mg as combination therapy 4:

• This addresses both erectile dysfunction and storage symptoms simultaneously
• Real-world evidence shows mean IPSS reduction of 4.18 points and OABSS reduction of 1.86 points 4
• 76% of patients achieve clinically meaningful IPSS improvement 4
• The combination improves erectile function scores (mean IIEF-5 increase of 2.92 points) without increasing urinary retention risk 4

Alternative approach if combination therapy is not suitable:

• Beta-3 agonist (mirabegron) alone for overactive bladder symptoms 3, 5
• Alpha-1 blockers if voiding symptoms predominate 5
• Anticholinergics as second-line for storage symptoms, though use caution in elderly patients 6, 7

Escalation Pathway if First-Line Fails

For Persistent Erectile Dysfunction

Refer to urology or sexual health specialist for second-line options 1:

1. Intraurethral prostaglandin pellet (MUSE)
2. Intracavernosal prostaglandin injection
3. Vacuum erection device
4. Combination therapy (e.g., sildenafil plus vacuum constriction)
5. Penile prosthesis as third-line surgical option

For Persistent Urinary Symptoms

Escalate based on symptom pattern 6, 7:

• For storage symptoms: Progress from beta-3 agonists to anticholinergics, then consider Botox injection or sacral neuromodulation
• For stress incontinence (if present): Start with pelvic floor muscle exercises, then consider penile clamps, and finally surgical options (bulking agents, male slings, artificial urinary sphincter) after 6-12 months 6, 7

Critical Pitfalls to Avoid

1. Don't dismiss symptoms as "just aging": The temporal relationship to cancer treatment and documented progression (IPSS 3→7) clearly indicate treatment-related etiology 1

2. Don't delay treatment: Many men never try medications or devices for ED after prostate cancer treatment; primary care clinicians must proactively open this discussion 1

3. Don't assume PDE-5 inhibitors won't work if previously tried: Erectile function can recover for 2-4 years post-surgery, so revisit even if initially unsuccessful 1

4. Screen for nitrate use: Always verify before prescribing PDE-5 inhibitors 3

5. Don't wait too long for surgical referral: If medical management fails after appropriate trials, refer to urology rather than accepting persistent dysfunction 1

6. Address psychosocial impact: These symptoms cause significant quality-of-life impairment, relationship strain, and social isolation; consider counseling referral 1

Monitoring and Reassessment

• Use validated questionnaires (IPSS, IIEF-5, OABSS) at baseline and follow-up to objectively track treatment response 6, 4
• Early reassessment is crucial: Evaluate response within 4-8 weeks, as clinical benefit may be clearer for some symptoms than others 4
• Monitor for adverse effects: PDE-5 inhibitors are generally well-tolerated, but combination therapy requires monitoring for side effects (6% adverse event rate in real-world data) 4